65487-32-3

Usage

Non-steroidal anti-inflammatory drug (NSAID)

It is a medication used to reduce pain and inflammation, commonly prescribed for conditions like arthritis, menstrual cramps, and other acute or chronic pain.

Inhibition of prostaglandin production

The compound works by inhibiting the production of prostaglandins, which are chemicals in the body responsible for causing inflammation and pain.

Fluorophenyl group

The presence of a 3-fluorophenyl group in the molecule contributes to its anti-inflammatory properties and helps in the inhibition of prostaglandin production.

Administration

2-(3-fluorophenyl)propionic acid is typically administered orally in the form of tablets or capsules, making it a convenient and accessible treatment option for patients.

Side effects

As with other NSAIDs, 2-(3-fluorophenyl)propionic acid may cause side effects such as gastrointestinal issues, increased risk of bleeding, and kidney problems. It is essential to consult a healthcare professional before using this medication.

Drug interactions

Patients using other medications, especially other NSAIDs, blood thinners, or corticosteroids, should inform their healthcare provider before starting treatment with 2-(3-fluorophenyl)propionic acid to avoid potential drug interactions and complications.

Upstream product

• 331-25-9 (3-fluorophenyl)acetic acid 
• 74-88-4 methyl iodide 
• 64-18-6 formic acid 
• 350-51-6 3-fluorostyrene 
• 1073-06-9 3-fluorobromobenzene 
• 56985-74-1 2-bromopropionic acid sodium salt 
• 124-38-9 carbon dioxide 
• 587-47-3 3-fluorophenylacetic acid ethyl ester 
• 65487-30-1 ethyl 2-(3-fluorophenyl)propanoate 

Relevant academic research and scientific papers

2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists

A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.

Ligand-Controlled Regioselective Hydrocarboxylation of Styrenes with CO2 by Combining Visible Light and Nickel Catalysis

The ligand-controlled Markovnikov and anti-Markovnikov hydrocarboxylation of styrenes with atmospheric pressure of CO2 at room temperature using dual visible-light-nickel catalysis has been developed. In the presence of neocuproine as ligand, the Markovnikov product is obtained exclusively, while employing 1,4-bis(diphenylphosphino)butane (dppb) as the ligand favors the formation of the anti-Markovnikov product. A range of functional groups and electron-poor, -neutral, as well as electron-rich styrene derivatives are tolerated by the reaction, providing the desired products in moderate to good yields. Preliminary mechanistic investigations indicate the generation of a nickel hydride (H-NiII) intermediate, which subsequently adds irreversibly to styrenes.

Flurbiprofen synthesis method

The invention relates to a flurbiprofen synthesis method and belongs to the technical field of pharmaceutical synthesis. According to the flurbiprofen synthesis method, Suzuki coupling reaction is utilized, the flurbiprofen can be obtained from 2-(3-fluoro-4-bromophenyl) propionic acid and phenyl boron reagent in organic solvent in the alkali condition through palladium catalytic Suzuki coupling reaction; the mole ratio between the 2-(3-fluoro-4-bromophenyl) propionic acid and the phenyl boron reagent is 1: (0.9 to 1.1). The synthesis method is simple, and the obtained flurbiprofen is high in yield and high in purity.

A Ligand-Directed Catalytic Regioselective Hydrocarboxylation of Aryl Olefins with Pd and Formic Acid

An effective Pd-catalyzed hydrocarboxylation of aryl olefins with Ac2O and formic acid is described. A variety of 2- and 3-arylpropanoic acids can be regioselectively formed by the judicious choice of ligand without the use of toxic CO gas.

GAMMA SECRETASE MODULATORS

The present invention provides compounds that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions conta